NO20072024L - Type 1 blokkeringsmidler for forebygging og behandling av psoriasis - Google Patents

Type 1 blokkeringsmidler for forebygging og behandling av psoriasis

Info

Publication number
NO20072024L
NO20072024L NO20072024A NO20072024A NO20072024L NO 20072024 L NO20072024 L NO 20072024L NO 20072024 A NO20072024 A NO 20072024A NO 20072024 A NO20072024 A NO 20072024A NO 20072024 L NO20072024 L NO 20072024L
Authority
NO
Norway
Prior art keywords
type
psoriasis
ifn
prevention
treatment
Prior art date
Application number
NO20072024A
Other languages
English (en)
Norwegian (no)
Inventor
Michel Gilliet
Frank O Nestle
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of NO20072024L publication Critical patent/NO20072024L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20072024A 2004-10-07 2007-04-20 Type 1 blokkeringsmidler for forebygging og behandling av psoriasis NO20072024L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04405628 2004-10-07
PCT/CH2005/000566 WO2006037247A1 (en) 2004-10-07 2005-09-30 Type i interferon blocking agents for prevention and treatment of psoriasis

Publications (1)

Publication Number Publication Date
NO20072024L true NO20072024L (no) 2007-04-26

Family

ID=35593663

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072024A NO20072024L (no) 2004-10-07 2007-04-20 Type 1 blokkeringsmidler for forebygging og behandling av psoriasis

Country Status (15)

Country Link
US (1) US20090155286A1 (pt)
EP (2) EP2286835A1 (pt)
JP (1) JP2008515819A (pt)
KR (1) KR20070083809A (pt)
CN (1) CN101056654A (pt)
AU (1) AU2005291741B2 (pt)
BR (1) BRPI0516470A (pt)
CA (1) CA2582471A1 (pt)
IL (1) IL182087A0 (pt)
MX (1) MX2007003809A (pt)
NO (1) NO20072024L (pt)
NZ (1) NZ554065A (pt)
RU (2) RU2007116988A (pt)
WO (1) WO2006037247A1 (pt)
ZA (1) ZA200702794B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002246955B2 (en) 2001-01-09 2007-03-22 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US7888481B2 (en) 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
RU2431638C2 (ru) 2005-02-10 2011-10-20 Бэйлор Рисерч Инститьют Моноклональные антитела против интерферона-альфа и способы применения
AU2009245792B2 (en) 2008-05-07 2012-11-01 Coimmune, Inc. Humanized antibodies against human interferon-alpha
FR2968561B1 (fr) * 2010-12-13 2013-08-09 Lfb Biotechnologies Utilisation d'un anticorps dirige contre une proteine membranaire
EP2623978A1 (en) * 2012-02-03 2013-08-07 Charité - Universitätsmedizin Berlin CD8+ T-cell subsets as markers for prediction of delayed fracture healing
CN103319608B (zh) * 2013-07-01 2014-08-27 江苏众红生物工程创药研究院有限公司 猪IFNɑ1-Fc融合蛋白及其编码基因和表达方法
WO2015095143A1 (en) 2013-12-16 2015-06-25 The University Of North Carolina At Chapel Hill Depletion of plasmacytoid dendritic cells
CN114292331A (zh) * 2013-12-24 2022-04-08 安斯泰来制药株式会社 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
JP7308034B2 (ja) 2016-07-01 2023-07-13 リゾルブ セラピューティクス， エルエルシー 最適化二重ヌクレアーゼ融合物および方法
WO2019040674A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc SOLUBLE INTERFERON RECEPTORS AND USES THEREOF
EP3801599A1 (en) * 2018-06-01 2021-04-14 ILC Therapeutics Ltd Compositions and methods relating to the treatment of diseases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423147A (en) * 1980-04-11 1983-12-27 Secher David S Monoclonal antibody to interferon-α
US4362155A (en) * 1981-03-24 1982-12-07 Skurkovich Simon V Method and apparatus for the treatment of autoimmune and allergic diseases
US4824432A (en) * 1981-03-24 1989-04-25 S.V.S. Laboratories, Inc. Method for treating AIDS and other immune deficiencies and immune disorders
US4605394A (en) * 1982-12-03 1986-08-12 Simon V. Skurkovich Methods for the treatment of pathological conditions by removing interferon from the organism
DE3211263A1 (de) * 1981-03-31 1983-01-27 Otsuka Pharmaceutical Co. Ltd., Tokyo Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung
EP0139676B1 (en) * 1983-02-04 1992-11-25 Cytoclonal Pharmaceutics Inc. Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
FR2560212B1 (fr) * 1984-02-24 1989-12-29 Unicet Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
EP0563487A1 (en) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
AUPP670698A0 (en) * 1998-10-23 1998-11-19 Monash University A method of regulation
DE19919149A1 (de) 1999-04-27 2000-11-16 Wieser Raimund J Von Interferon alpha-2 abgeleitete Peptid-Homodimere und Peptid-Heterodimere
EP1783141A1 (en) * 1999-11-15 2007-05-09 Miltenyi Biotec GmbH Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
GB0001710D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
GB0001712D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic peptides
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
AU2002246955B2 (en) * 2001-01-09 2007-03-22 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
NZ540555A (en) * 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
KR101151477B1 (ko) * 2003-12-10 2012-06-22 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
RU2431638C2 (ru) * 2005-02-10 2011-10-20 Бэйлор Рисерч Инститьют Моноклональные антитела против интерферона-альфа и способы применения

Also Published As

Publication number Publication date
NZ554065A (en) 2010-12-24
US20090155286A1 (en) 2009-06-18
KR20070083809A (ko) 2007-08-24
AU2005291741B2 (en) 2011-11-24
AU2005291741A1 (en) 2006-04-13
IL182087A0 (en) 2007-07-24
WO2006037247A1 (en) 2006-04-13
RU2007116988A (ru) 2008-11-20
RU2010146161A (ru) 2012-05-20
EP1796722A1 (en) 2007-06-20
ZA200702794B (en) 2008-06-25
CN101056654A (zh) 2007-10-17
JP2008515819A (ja) 2008-05-15
BRPI0516470A (pt) 2008-09-09
EP2286835A1 (en) 2011-02-23
CA2582471A1 (en) 2006-04-13
MX2007003809A (es) 2007-09-12

Similar Documents

Publication Publication Date Title
NO20072024L (no) Type 1 blokkeringsmidler for forebygging og behandling av psoriasis
Roth et al. Flavivirus infection uncouples translation suppression from cellular stress responses
NO20084931L (no) Farmasoytiske sammensetninger
ATE510841T1 (de) Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
GT200100183A (es) Derivados de quinolina y quinazolina.
NO20082311L (no) Terapeutisk middel for hjertesykdom
NO20080487L (no) Rekominant interferona2 (IFNa2) mutanter
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
NO20052626D0 (no) Middel for forhindring eller behandling av neuropati
NO20076093L (no) Substituerte amidderivater som proteinkinaseinhibitorer
ATE325125T1 (de) Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden
NO20074084L (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikamenter og medikamenter inneholdende disse
ATE550032T1 (de) Verwendung von glp-1, exendin und agonisten davon zur verzögerung oder verhinderung von kardialer remodellierung
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
EP3940826A4 (en) PRODUCTION PROCESS FOR ELECTRODE BONDER AND ELECTRODE ASSEMBLY WITH THE ELECTRODE BINDER
BR112021026531A2 (pt) Composto, composição farmacêutica, e, método para prevenir ou tratar uma doença mediada pela tirosina cinase 2
DE602005010821D1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
DK1455761T3 (da) Farmaceutiske præparater til oral administration af heparin eller derivater deraf
DE602006020246D1 (de) Modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kb-aktivität und deren verwendung
ATE446385T1 (de) Polymorphismen im nod2/card15 gen
NO20051138L (no) Nye farmasoytiske formuleringer av modafinil
WO2009069132A3 (en) Novel reverse transcriptase inhibitors
EP4342900A4 (en) SESQUITERPENE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF, PROCESS FOR THEIR PREPARATION AND THEIR USE

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application